|本期目录/Table of Contents|

[1]褚瑜光,胡元会.冠状动脉粥样硬化性心脏病心力衰竭患者血栓形成动力学特征研究[J].国际心血管病杂志,2016,02:120-122.
　CHU Yuguang,HU Yuanhui..Kinetics characteristics of thrombogenesis in patients with coronary heart disease complicated with heart failure[J].International Journal of Cardiovascular Disease,2016,02:120-122.
点击复制

冠状动脉粥样硬化性心脏病心力衰竭患者血栓形成动力学特征研究(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年02期
页码:
120-122
栏目:
临床研究
出版日期:
2016-03-20

文章信息/Info

Title:
Kinetics characteristics of thrombogenesis in patients with coronary heart disease complicated with heart failure
作者:
褚瑜光; 胡元会
100053 中国中医科学院广安门医院心内科
Author(s):
CHU Yuguang;  HU Yuanhui.
关键词:
心力衰竭; 血栓弹力图; 血栓风险
Keywords:
Heart failure;  Thromboela-stogram;  Thrombogenesis risk
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.02.016
文献标识码:
-
摘要:
目的:运用血栓弹力图(thromboela-stogram,TEG)评价冠状动脉粥样硬化性心脏病(冠心病)心力衰竭患者的血栓风险。方法:入选120例冠心病患者,其中非心力衰竭(NHF)组46例,心力衰竭(HF)组74例。所有患者均进行TEG检测,比较两组患者的TEG指标。结果:NHF组凝血反应时间(R)、血凝块形成时间(K)均高于HF组;NHF组描记图曲线最大弧度的切线与水平线夹角(Angle)、花生四烯酸通道诱导的血小板活性抑制率(AA%)低于HF组(P均<0.05);冠心病患者心力衰竭的发生与R
Abstract:
Objective: To evaluate the thrombogenesis risk of patients with coronary heart disease complicated with heart failure(HF)by thromboela-stogram(TEG).Methods: A total of 120 patients with coronary heart disease were enrolled and divided into heart failure

参考文献/References

[1] 马 睿,任 静,门剑龙,等.慢性心力衰竭患者凝血功能的研究[J].天津医药,2013,1(41):65-66.
[2] 国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75.
[3] Qaseem A, Fihn SD, Williams S, et al. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/preventive Cardiovascular Nurses Association Society of Thoracic Surgeons [J]. Ann Intern Med, 2012,157(10):729-734.
[4] Bonow RO, Mann DL,Zipes DP,et al. Braunwald's Heart Disease: a textbook of cardiovascular medicine[M]. 9 th ed. Philaclephia, PA: Saunders Elsevier, 2012:1251.
[5] 李锡昌. 探讨高血压合并不稳定型心绞痛患者发作急性左心衰的危险因素[J]. 中国实用医药,2015,17(10):126-127.
[6] Massie BM,Krol WF,Ammon SE,et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial(WATCH): rationale, design, and baseline patient characteristics [J].J Card Fail,2004, 10(2): 101-112.
[7] Cleland JG,Findlay I,Jafri S,et al.The Warafrin/Aspirin Study in Heart Failure(WASH):a randomized trial comparing antithrombotic strategies for patents with heart failure[J]. Am Heart J,2004, 148(1)157-164.
[8] Freudenberger RS,Schumaecker MM,Homma S.What is the appropriate approach to prevention of thromboembolism in heart failure?[J].Thromb Haemost,2010,103(3):489-495.
[9] 宋芝萍,张 鹏,关 平.B型利钠肽在评估慢性房颤患者左心房血栓形成的价值[J].国际心血管病杂志,2013,40(2):122-124.
[10] 李茂巍,张必利,郑 兴.高龄冠心病患者PCI后院内死亡危险因素分析[J].国际心血管病杂志,2015,42(1):56-58.
[11] Reilly M, Fitzgerald GA. Cellular activation by thromboxane A2 and other eicosanoids. [J] Eur Heart,1993,14 Supply K:88-93.
[12] Delgado RM, Nawar MA, Zewail AM, et al.Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in am urine model of doxorubicin-induced heart failure[J]. Circulation,2004,109(11):1428-1433.
[13] 王 华,杨杰孚,张传宝,等. 慢性心力衰竭患者凝血功能及C反应蛋白的改变[J]. 中国循环杂志,2006,21(3):388-392.
[14] 闫璐璐,张永珍. 花生四烯酸细胞色素P450代谢途径在心力衰竭中作用的研究进展[J]. 中国心血管杂志,2015,20(2):151-154.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81373833) 作者单位:100053 中国中医科学院广安门医院心内科 通信作者:胡元会,Email:Huiyuhui55@sohu.com
更新日期/Last Update: 2016-03-20